OCDX - Ortho's COVID-19 antigen test receives CE mark shares up 5%

Ortho Clinical Diagnostics (OCDX) has received CE Marking for its VITROS SARS-CoV-2 Antigen Test, initially launched in October 2020.The CE Mark allows for more convenient sample collection and expanded viral transport media ((VTM)).Laboratories will now be able to utilize three additional VTM options.The VITROS SARS-CoV-2 Antigen Test now demonstrates 98 and 92.3% sensitivity for samples with a PCR cycle threshold of less than 30.OCDX shares up 5% premarket trading at $19.57.

For further details see:

Ortho's COVID-19 antigen test receives CE mark, shares up 5%